Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 15/20 | 0.48 |
| ▸ | TUBB4A | P04350 | 3/20 | 0.43 |
| ▸ | TUBB | P07437 | 3/20 | 0.43 |
| ▸ | TUBA3C | P0DPH7 | 3/20 | 0.43 |
| ▸ | TUBA1B | P68363 | 3/20 | 0.43 |
| ▸ | TUBA4A | P68366 | 3/20 | 0.43 |
| ▸ | TUBB4B | P68371 | 3/20 | 0.43 |
| ▸ | TUBB3 | Q13509 | 3/20 | 0.43 |
| ▸ | TUBB2A | Q13885 | 3/20 | 0.43 |
| ▸ | TUBB8 | Q3ZCM7 | 3/20 | 0.43 |
| ▸ | TUBA3E | Q6PEY2 | 3/20 | 0.43 |
| ▸ | TUBA1A | Q71U36 | 3/20 | 0.43 |
| ▸ | TUBA1C | Q9BQE3 | 3/20 | 0.43 |
| ▸ | TUBB6 | Q9BUF5 | 3/20 | 0.43 |
| ▸ | TUBB2B | Q9BVA1 | 3/20 | 0.43 |
| ▸ | TUBB1 | Q9H4B7 | 3/20 | 0.43 |
| ▸ | SMO | Q99835 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL438045 | 0.82 | EPHX1 (0.54) | DGAT1TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL442251 | 0.82 | MEN1 (0.51) | DGAT1TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL441511 | 0.82 | EPHX2 (0.53) | DGAT1TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL441745 | 0.80 | DGAT1 (0.51) | DGAT1TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL441744 | 0.80 | DGAT1 (0.51) | DGAT1TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL443378 | 0.79 | DGAT1 (0.54) | DGAT1 | |
| SCHEMBL440841 | 0.79 | DGAT1 (0.52) | DGAT1 | |
| SCHEMBL442980 | 0.79 | TSHR (0.51) | DGAT1 | |
| SCHEMBL437965 | 0.79 | DGAT1 (0.54) | DGAT1 | |
| SCHEMBL440469 | 0.78 | EPHX2 (0.54) | DGAT1TUBB4ATUBBTUBA3CTUBA1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120065196-A1 | AMIDE COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-03-15 | — | — | US | disclosed |
| US-20120065196-A1 | AMIDE COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120065196-A1 | AMIDE COMPOUNDS | DGAT2, DGAT1, DLAT | DGAT1 2/4885TUBB4A 1850/4885TUBB 1604/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.